Zhaohan Wei
Overview
Explore the profile of Zhaohan Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu H, Xu S, Yong T, Wei Z, Bie N, Zhang X, et al.
Adv Mater
. 2025 Mar;
:e2502404.
PMID: 40026023
No abstract available.
2.
Bie N, Li S, Liang Q, Zheng W, Xu S, Liu H, et al.
Mol Pharm
. 2025 Jan;
22(2):733-746.
PMID: 39772575
Traditional chemotherapy often encounters failure attributed to drug resistance mediated by tumor-repopulating cells (TRCs) and chemotherapy-triggered immune suppression. The effective inhibition of TRCs and the mitigation of drug-induced immune suppression...
3.
Qin J, Liu J, Wei Z, Li X, Chen Z, Li J, et al.
Nat Nanotechnol
. 2024 Nov;
20(2):311-324.
PMID: 39496914
Nerve-cancer crosstalk has gained substantial attention owing to its impact on tumour growth, metastasis and therapy resistance. Effective therapeutic strategies targeting tumour-associated nerves within the intricate tumour microenvironment remain a...
4.
Zheng W, Li J, Li J, Bie N, Wei Z, Qin J, et al.
J Control Release
. 2024 Sep;
375:316-330.
PMID: 39251139
In addition to residual tumor cells, surgery-induced inflammation significantly contributes to tumor recurrence and metastasis by recruiting polymorphonuclear neutrophils (PMNs) and promoting their involvement in tumor cell proliferation, invasion and...
5.
Chen Z, Yong T, Wei Z, Zhang X, Li X, Qin J, et al.
Adv Sci (Weinh)
. 2023 Nov;
11(3):e2305081.
PMID: 38009498
Cancer vaccines hold great potential for clinical cancer treatment by eliciting T cell-mediated immunity. However, the limited numbers of antigen-presenting cells (APCs) at the injection sites, the insufficient tumor antigen...
6.
Bie N, Yong T, Wei Z, Liang Q, Zhang X, Li S, et al.
Signal Transduct Target Ther
. 2023 Oct;
8(1):408.
PMID: 37875473
Immune checkpoint blockade (ICB) therapy, particularly antibodies targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, its efficacy as a standalone therapy remains...
7.
Liu H, Xu S, Yong T, Wei Z, Bie N, Zhang X, et al.
Adv Mater
. 2023 Sep;
35(45):e2211980.
PMID: 37755231
Tumor-cell-derived microparticles (MPs) can function as anticancer drug-delivery carriers. However, short blood circulation time, large-size-induced insufficient tumor accumulation and penetration into tumor parenchyma, as well as limited cellular internalization by...
8.
Zhang X, Wei Z, Yong T, Li S, Bie N, Li J, et al.
Nat Commun
. 2023 Sep;
14(1):5653.
PMID: 37704614
The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited...
9.
Bie N, Yong T, Wei Z, Gan L, Yang X
Adv Drug Deliv Rev
. 2022 Jul;
188:114450.
PMID: 35841955
Extracellular vesicles (EVs), including microparticles and exosomes, have emerged as potential tools for tumor targeting delivery during the past years. Recently, mass of strategies are applied to assist EVs to...
10.
Yong T, Wei Z, Gan L, Yang X
Adv Mater
. 2022 Jun;
34(52):e2201054.
PMID: 35726204
Although immunotherapy harnessing activity of the immune system against tumors has made great progress, the treatment efficacy remains limited in most cancers. Current anticancer immunotherapy is primarily based on T-cell-mediated...